Business Description
Soleno Therapeutics Inc
NAICS : 541713
SIC : 2834
ISIN : US8342032005
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 431.2 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 32.3 | |||||
3-Year EPS without NRI Growth Rate | 34 | |||||
3-Year FCF Growth Rate | 37 | |||||
3-Year Book Growth Rate | -16.6 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 46.83 | |||||
9-Day RSI | 46.06 | |||||
14-Day RSI | 47.17 | |||||
6-1 Month Momentum % | 60.38 | |||||
12-1 Month Momentum % | 675.55 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 11.23 | |||||
Quick Ratio | 11.23 | |||||
Cash Ratio | 11.11 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -81.4 | |||||
Shareholder Yield % | -8.78 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -76.7 | |||||
ROA % | -56.12 | |||||
ROIC % | -292.49 | |||||
ROC (Joel Greenblatt) % | -14039.31 | |||||
ROCE % | -68.15 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 9.91 | |||||
Price-to-Tangible-Book | 10.62 | |||||
EV-to-EBIT | -25.29 | |||||
EV-to-EBITDA | -26.24 | |||||
EV-to-Forward-Revenue | 7.82 | |||||
EV-to-FCF | -46.23 | |||||
Price-to-Net-Current-Asset-Value | 11.41 | |||||
Price-to-Net-Cash | 11.55 | |||||
Earnings Yield (Greenblatt) % | -3.96 | |||||
FCF Yield % | -2.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Soleno Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -2.508 | ||
Beta | -2.76 | ||
Volatility % | 458.23 | ||
14-Day RSI | 47.17 | ||
14-Day ATR (€) | 1.406593 | ||
20-Day SMA (€) | 39.631 | ||
12-1 Month Momentum % | 675.55 | ||
52-Week Range (€) | 3.37 - 47.4 | ||
Shares Outstanding (Mil) | 36.86 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Soleno Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Soleno Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Soleno Therapeutics Inc Frequently Asked Questions
What is Soleno Therapeutics Inc(STU:6XC)'s stock price today?
When is next earnings date of Soleno Therapeutics Inc(STU:6XC)?
Does Soleno Therapeutics Inc(STU:6XC) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |